Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer.
anti-EGFR
liquid biopsy
metastatic colorectal cancer (mCRC)
rechallenge
reintroduction
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
05
2022
accepted:
20
09
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
In patients with
Identifiants
pubmed: 36818675
doi: 10.3389/fonc.2022.946850
pmc: PMC9932317
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
946850Informations de copyright
Copyright © 2023 Cremolini, Montagut, Ronga, Venturini, Yamaguchi, Stintzing and Sobrero.
Déclaration de conflit d'intérêts
CC reports honoraria and consultancy from Bayer, Amgen, Merck, Roche, and Servier, and research funding from Merck and Roche. CM reports scientific consultancy role, travel grants or research grants past 5 years from Amgen, Biocartis, BMS, Guardant-Health, Merck-Serono, Roche, Sanofi Aventis, and SeaGen. PR reports employment with Merck Healthcare KGaA, Darmstadt, Germany. FV reports employment with Merck Serono S.p.A., Italy, an affiliate of Merck KGaA, Darmstadt, Germany. KY reports consultancy/advisory from Daiichi-Sankyo and Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA; research support from Ono Pharmaceutical and Taiho Pharmaceutical; research grants from Ono Pharmaceutical, Taiho Pharmaceutical, Yakult Honsha, Daiichi-Sankyo, Chugai Pharm, Takeda, Lilly, Sanofi, MSD Oncology, Dainippon Sumitomo Pharma, Gilead Sciences, Boehringer lngelheim, Eisai, and Yakult Honsha; and speaker/honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, Daiichi-Sankyo, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Chugai Pharm, Bristol Myers Squibb Japan, Takeda, Lilly, and Sanofi. SS reports honoraria for presentations and advisory board role from Amgen, Bayer, Lilly, Merck Healthcare KGaA, Darmstadt, Germany, MSD, Pierre-Fabre, Roche, Sanofi, Servier, Taiho, and Takeda. AS reports consulting and speakers’ bureau from Roche, Merck Healthcare KGaA, Darmstadt, Germany, Amgen, BMS, Lilly, Celgene, Sanofi, Bayer, and Takeda.
Références
Cancer Biol Ther. 2013 Dec;14(12):1143-6
pubmed: 24025416
Cancer Treat Rev. 2016 Dec;51:54-62
pubmed: 27865140
Onco Targets Ther. 2019 Mar 27;12:2271-2278
pubmed: 30988631
Nat Med. 2015 Jul;21(7):827
pubmed: 26151329
Clin Colorectal Cancer. 2022 Jun;21(2):141-148
pubmed: 35101346
Cancers (Basel). 2021 Nov 15;13(22):
pubmed: 34830870
Cancers (Basel). 2021 Sep 07;13(18):
pubmed: 34572729
N Engl J Med. 2009 Apr 2;360(14):1408-17
pubmed: 19339720
Ann Oncol. 2020 Jan;31(1):30-40
pubmed: 31912793
Nat Med. 2022 Aug;28(8):1612-1618
pubmed: 35915157
Lancet Oncol. 2010 Aug;11(8):753-62
pubmed: 20619739
JAMA Oncol. 2015 Sep;1(6):787-95
pubmed: 26181239
BMC Cancer. 2015 Oct 16;15:713
pubmed: 26474549
Clin Colorectal Cancer. 2021 Dec;20(4):314-317
pubmed: 34364814
Ann Oncol. 2018 May 1;29(5):1211-1219
pubmed: 29438522
Visc Med. 2016 Jun;32(3):178-83
pubmed: 27493945
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Clin Cancer Res. 2017 May 15;23(10):2414-2422
pubmed: 27780856
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22
pubmed: 12857956
JAMA Oncol. 2019 Mar 1;5(3):343-350
pubmed: 30476968
Ann Oncol. 2022 Aug;33(8):750-768
pubmed: 35809752
Cancers (Basel). 2021 Apr 17;13(8):
pubmed: 33920531
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Nat Rev Clin Oncol. 2020 Dec;17(12):757-770
pubmed: 32632268
Cancer Discov. 2018 Feb;8(2):164-173
pubmed: 29196463
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
Cancer Res. 2006 Apr 15;66(8):3992-5
pubmed: 16618717
Nat Med. 2012 Jan 22;18(2):221-3
pubmed: 22270724
Ann Oncol. 2019 Feb 1;30(2):243-249
pubmed: 30462160
Cancer Discov. 2014 Nov;4(11):1269-80
pubmed: 25293556
JAMA. 2018 Jun 26;319(24):2486-2496
pubmed: 29946728
Biomark Insights. 2019 Feb 01;14:1177271919826545
pubmed: 30745794
JAMA Oncol. 2019 Jan 1;5(1):83-90
pubmed: 30422156
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Cancer Res. 2007 Mar 15;67(6):2643-8
pubmed: 17363584
Target Oncol. 2021 Nov;16(6):753-760
pubmed: 34718946
Oncol Lett. 2018 Sep;16(3):3674-3680
pubmed: 30127977
JAMA Oncol. 2021 Oct 01;7(10):1529-1535
pubmed: 34382998
Ann Oncol. 2018 Jan 1;29(1):119-126
pubmed: 28945848
Clin Cancer Res. 2015 May 1;21(9):2157-66
pubmed: 25623215
Oncotarget. 2017 Nov 16;9(7):7739-7748
pubmed: 29484148
Nature. 2015 Oct 8;526(7572):263-7
pubmed: 26416732
Br J Cancer. 2020 Nov;123(10):1490-1495
pubmed: 32863385
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
J Exp Clin Cancer Res. 2013 Nov 18;32:92
pubmed: 24245912
Cancer Treat Rev. 2019 Feb;73:41-53
pubmed: 30616224
JCO Precis Oncol. 2020 Nov;4:898-911
pubmed: 35050760
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
JAMA Oncol. 2018 Apr 12;4(4):e175245
pubmed: 29423521
N Engl J Med. 2004 Jul 22;351(4):337-45
pubmed: 15269313
Ecancermedicalscience. 2020 Jul 13;14:1069
pubmed: 32728385
Nat Commun. 2016 Dec 08;7:13665
pubmed: 27929064
Ann Oncol. 2018 Apr 1;29(4):835-856
pubmed: 29452346
Front Oncol. 2022 Apr 21;12:852583
pubmed: 35530345
Front Oncol. 2022 Jun 27;12:940523
pubmed: 35832541
Clin Colorectal Cancer. 2020 Sep;19(3):191-199.e6
pubmed: 32466976
Ann Oncol. 2012 Sep;23(9):2313-2318
pubmed: 22396447
ESMO Open. 2018 May 5;3(4):e000353
pubmed: 29765773
Ann Oncol. 2019 Feb 1;30(2):259-265
pubmed: 30508156
Eur J Cancer. 2017 Sep;83:106-115
pubmed: 28735067
Sci Transl Med. 2012 May 30;4(136):136ra68
pubmed: 22649089
Cancer Discov. 2013 Jun;3(6):658-73
pubmed: 23729478
Cancer Manag Res. 2019 Feb 19;11:1705-1716
pubmed: 30863179
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050